First-of-Its-Kind Testing Device Allows For Rapid Detection of Bacteria That Identify Risk for Preterm Birth
|
By LabMedica International staff writers Posted on 14 Oct 2021 |

A newly-developed cost-effective device can rapidly and accurately detect changes in vaginal bacteria and corresponding immune responses in pregnant women, which are associated with increased risk of preterm birth.
The first-of-its-kind testing device developed by researchers at the March of Dimes Prematurity Research Center at Imperial College London (London, UK) may help advance diagnosis and treatment of preterm birth by facilitating faster clinical decision-making and helping improve targeted treatment strategies during pregnancy.
Preterm birth remains a major cause of death worldwide in children under age five. One of the many factors that contribute to a woman's risk of preterm birth is changes during pregnancy to the type and amounts of microbes in the lower reproductive tract, referred to as the vaginal microbiome. In some women, certain bacteria from the microbiome can cause inflammation leading to an increased risk of preterm birth. The new testing device called direct-on-swab metabolic profiling by Desorption Electrospray Ionization Mass Spectrometry (DESI-MS), rapidly analyzes chemicals in a clinical swab to simultaneously determine the type of bacteria in the vagina, and corresponding immune or inflammatory response to the bacteria.
The two-minute test was found to be just as effective as 'gold standard' chemical profiling tests (e.g. Liquid Chromatography-Mass Spectrometry assays) that require detailed sample preparation and extraction making them more time consuming (up to eight hours per assay), costly and difficult to introduce into routine bedside testing. The ability to monitor the vaginal microbiome and inflammation throughout pregnancy with DESI-MS could help identify women at risk of preterm birth sooner, potentially allowing obstetricians to monitor these women more closely and start preventative treatments earlier and in a more targeted way than currently possible.
The researchers tested the direct-on-swab DESI-MS device by analyzing more than 1,000 samples collected from two independent groups of pregnant women (about 400 women in total) in the UK. The data found that women who had changing and diverse vaginal microbiomes (those that contained many different bacteria or had bacteria that changed during pregnancy) had higher rates of preterm birth and were more likely to have increased inflammation. The test also detected inflammation caused by some treatments received during pregnancy (e.g. a stitch put into the cervix for 'cervical cerclage' treatment). This inflammation was most frequently observed in women subsequently experiencing preterm birth.
The device may have broader application to other areas of women's health where the vaginal microbiome has been implicated, including bacterial vaginosis, HIV and HPV infection, cervical dysplasia, IVF failure and miscarriage. The researchers now plan to register the technology and seek regulatory approval for its use in the UK and Europe and, eventually, in North America. They also are planning development of a miniature version of the test that can be used more widely in clinics and would allow for bedside testing.
"We've known for some time that the vaginal microbiome can contribute to the risk of preterm birth, but now we have developed a device which in just a few minutes can report both the microbiome composition and inflammatory status of a sample collected during pregnancy," said Dr. David MacIntyre, Reader in Reproductive Systems Medicine, Institute of Reproductive and Developmental Biology Department of Metabolism, Digestion and Reproduction at Imperial College London. "This is the first rapid testing device of its kind and could be readily transferred to use in a clinical setting. This information could be used by doctors and patients to monitor risk of preterm birth but also to help optimize treatments, such as more selective use of antibiotics."
Related Links:
Imperial College London
Latest Pathology News
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
- Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read moreMicrobiology
view channelRapid Color Test Stratifies Virulent and Resistant Staph Strains
Staphylococcus aureus (golden staph) remains a leading cause of infection-related mortality worldwide, responsible for more than a million deaths each year. Rapidly distinguishing highly virulent or a... Read more
Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read morePathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more







